AEZS vs. ATE, RVX, APS, MBX, BCT, HBP, WLLW, and VPH
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Antibe Therapeutics (ATE), Resverlogix (RVX), Aptose Biosciences (APS), Microbix Biosystems (MBX), BriaCell Therapeutics (BCT), Helix BioPharma (HBP), Willow Biosciences (WLLW), and Valeo Pharma (VPH). These companies are all part of the "medical" sector.
Antibe Therapeutics (TSE:ATE) and Aeterna Zentaris (TSE:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
In the previous week, Aeterna Zentaris had 2 more articles in the media than Antibe Therapeutics. MarketBeat recorded 2 mentions for Aeterna Zentaris and 0 mentions for Antibe Therapeutics. Aeterna Zentaris' average media sentiment score of 0.00 equaled Antibe Therapeutics'average media sentiment score.
Aeterna Zentaris has lower revenue, but higher earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
Aeterna Zentaris' return on equity of -52.72% beat Antibe Therapeutics' return on equity.
0.7% of Aeterna Zentaris shares are held by institutional investors. 7.9% of Antibe Therapeutics shares are held by insiders. Comparatively, 4.0% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Antibe Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.
Antibe Therapeutics received 181 more outperform votes than Aeterna Zentaris when rated by MarketBeat users. However, 88.89% of users gave Aeterna Zentaris an outperform vote while only 74.41% of users gave Antibe Therapeutics an outperform vote.
Summary
Aeterna Zentaris beats Antibe Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
